Published Online
on March 1, 2004

A more recent version of this article appeared on March 9, 2004

This Article Full Text (PDF) All Versions of this Article: 109/9/1085    most recent 01.CIR.0000121327.67756.19v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fujii, K. Articles by Moses, J. W. Search for Related Content PubMed PubMed Citation Articles by Fujii, K. Articles by Moses, J. W. Related Collections Restenosis

Submitted on December 1, 2003
Revised on January 16, 2004
Accepted on January 22, 2004

Contribution of Stent Underexpansion to Recurrence After Sirolimus-Eluting Stent Implantation for In-Stent Restenosis

Kenichi Fujii MD, Gary S. Mintz MD, Yoshio Kobayashi MD, Stéphane G. Carlier MD, PhD, Hideo Takebayashi MD, Takenori Yasuda MD, Issam Moussa MD, George Dangas MD, PhD, Roxana Mehran MD, Alexandra J. Lansky MD, Arlene Reyes MD, Edward Kreps MD, Michael Collins MD, Antonio Colombo MD, Gregg W. Stone MD, Paul S. Teirstein MD, Martin B. Leon MD, and Jeffrey W. Moses MD^*

From the Cardiovascular Research Foundation, Lenox Hill Heart and Vascular Institute, New York, NY.

^* To whom correspondence should be addressed. E-mail: jmoses{at}lenoxhill.net.

Background--We used intravascular ultrasound (IVUS) to evaluate recurrence after sirolimus-eluting stent (SES) implantation treatment of in-stent restenosis (ISR).

Methods and Results--Forty-eight ISR lesions (41 patients with objective evidence of ischemia) were treated with SES. Recurrent ISR was identified in 11 lesions (all focal); repeat revascularization was performed in 10. These were compared with 16 patients (19 lesions) without recurrence as documented by angiography. Nine of 11 recurrent lesions had a minimum stent area (MSA) <5.0 mm² versus 5 of 19 nonrecurrent lesions (P=0.003); 7 of 11 recurrent lesions had an MSA <4.0 mm² versus 4 of 19 nonrecurrent lesions (P=0.02); and 4 of 11 recurrent lesions had an MSA <3.0 mm² versus 1 of 19 nonrecurrent lesions (P=0.03). A gap between SESs was identified in 3 of 11 recurrences versus 1 of 19 nonrecurrent lesions.

Conclusions--Stent underexpansion is a significant cause of failure after SES implantation treatment of ISR.

Key words: ultrasonics • restenosis • stents

This article has been cited by other articles:

				P. Roy, D. H. Steinberg, S. J. Sushinsky, T. Okabe, T. L. P. Slottow, K. Kaneshige, Z. Xue, L. F. Satler, K. M. Kent, W. O. Suddath, et al. The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents Eur. Heart J., June 11, 2008; (2008) ehn249v1. [Abstract] [Full Text] [PDF]

				Y. Honda and P. J. Fitzgerald Frontiers in Intravascular Imaging Technologies Circulation, April 15, 2008; 117(15): 2024 - 2037. [Full Text] [PDF]

				C. Di Mario and P. Barlis Optical Coherence Tomography: A New Tool to Detect Tissue Coverage in Drug-Eluting Stents J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 174 - 175. [Full Text] [PDF]

				E. Romagnoli, G. M. Sangiorgi, J. Cosgrave, E. Guillet, and A. Colombo Drug-Eluting Stenting: The Case for Post-Dilation J. Am. Coll. Cardiol. Intv., February 1, 2008; 1(1): 22 - 31. [Abstract] [Full Text] [PDF]

				G. S. Mintz and N. J. Weissman Intravascular Ultrasound in the Drug-Eluting Stent Era J. Am. Coll. Cardiol., August 1, 2006; 48(3): 421 - 429. [Abstract] [Full Text] [PDF]

				F. Alfonso, M.-J. Perez-Vizcayno, R. Hernandez, A. Bethencourt, V. Marti, J. R. Lopez-Minguez, J. Angel, R. Mantilla, C. Moris, A. Cequier, et al. A Randomized Comparison of Sirolimus-Eluting Stent With Balloon Angioplasty in Patients With In-Stent Restenosis: Results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) Trial J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2152 - 2160. [Abstract] [Full Text] [PDF]

				M.-K. Hong, G. S. Mintz, C. W. Lee, D.-W. Park, B.-R. Choi, K.-H. Park, Y.-H. Kim, S.-S. Cheong, J.-K. Song, J.-J. Kim, et al. Intravascular ultrasound predictors of angiographic restenosis after sirolimus-eluting stent implantation Eur. Heart J., June 1, 2006; 27(11): 1305 - 1310. [Abstract] [Full Text] [PDF]

				A. Hoye, I. Iakovou, L. Ge, C. A.G. van Mieghem, A. T.L. Ong, J. Cosgrave, G. M. Sangiorgi, F. Airoldi, M. Montorfano, I. Michev, et al. Long-Term Outcomes After Stenting of Bifurcation Lesions With the "Crush" Technique: Predictors of an Adverse Outcome J. Am. Coll. Cardiol., May 16, 2006; 47(10): 1949 - 1958. [Abstract] [Full Text] [PDF]

				L. Ge, F. Airoldi, I. Iakovou, J. Cosgrave, I. Michev, G. M. Sangiorgi, M. Montorfano, A. Chieffo, M. Carlino, N. Corvaja, et al. Clinical and Angiographic Outcome After Implantation of Drug-Eluting Stents in Bifurcation Lesions With the Crush Stent Technique: Importance of Final Kissing Balloon Post-Dilation J. Am. Coll. Cardiol., August 16, 2005; 46(4): 613 - 620. [Abstract] [Full Text] [PDF]

				F. Alfonso Drug-Eluting Stents and In-Stent Restenosis JAMA, April 20, 2005; 293(15): 1855 - 1855. [Full Text] [PDF]

				F. Alfonso Optimal Implantation Strategies Using Drug-Eluting Stents for In-Stent Restenosis: Do We Know the Answer? Circulation, September 14, 2004; 110(11): e302 - e302. [Full Text] [PDF]